Saxenda Injections – Weight Loss Treatment

Saxenda injections for prescribed weight management

Saxenda is a prescription injectable medicine containing liraglutide. It is authorised for weight management in eligible patients with reduced-calorie eating and increased activity. Eligibility and continuation are clinical decisions. This variable listing may show different quantities; the selected option must match the prescription and dispensing label.

Product identity

• Brand: Saxenda
• Ingredient: liraglutide
• Concentration: 6mg/mL
• Presentation: pre-filled injection pen
• Pen content: 18mg in 3mL according to the authorised leaflet
• Status: prescription only

Liraglutide is a GLP-1 receptor agonist. Saxenda follows a clinician-led plan and is not interchangeable with liraglutide products licensed for other uses. Check pack quantity and accessories for the exact option supplied.

Assessment before use

A prescriber must assess body mass index, weight-related conditions, previous efforts, medicines and contraindications. Relevant history may include digestive, pancreatic, gallbladder, kidney, liver, thyroid and diabetes issues. Insulin or medicines that lower blood sugar require specific advice. Disclose all medicines and supplements.

Saxenda should not be used during pregnancy. Pregnancy plans and breastfeeding need discussion. Do not combine it with another GLP-1 or liraglutide medicine unless the clinician directs the change. Never share a pen.

Safe device use

The authorised plan introduces liraglutide in stages, but this page gives no individual dose. Follow the dispensing label, leaflet and professional training. Never alter the setting, repeat a dose, count clicks or extract liquid based on internet advice.

Injection is subcutaneous using the approved technique in the leaflet. A new compatible needle and sharps disposal may be required; check what the pack includes. For a missed dose, faulty pen or treatment interruption, contact the prescribing service instead of guessing how to restart.

Effects and warning signs

Common effects include nausea, vomiting, diarrhoea, constipation, headache and digestive discomfort. These can cause dehydration, especially relevant to kidney problems. Severe persistent abdominal pain may signal pancreatitis and needs urgent assessment. Seek immediate help for serious allergy. Gallbladder symptoms, fast heartbeat, mood changes or other worrying effects should be discussed promptly.

The leaflet contains the complete warnings and interactions. A prescriber may review response and tolerability. No amount of weight loss is guaranteed.

Storage and disposal

Unopened and in-use pens have specific temperature, light and time-limit rules. Follow the actual pack leaflet. Saxenda must not be frozen. Keep the cap on when directed, protect from children and discard needles in a sharps container.

Inspect the label, pen, solution, expiry and tamper evidence. Confirm 6mg/mL and the prescribed quantity. Contact Sano Med if delivery differs.

Comparisons

Saxenda differs from Wegovy semaglutide and orlistat. These links explain catalogue differences, not a recommendation to switch.

Frequently asked questions

Can it be selected without consultation?

No. Clinical screening, prescription and follow-up are required.

Are needles included?

Contents vary. Check the selected pack and arrange compatible needles and disposal if needed.

Where is official guidance?

Read the Saxenda patient leaflet and NHS liraglutide guide.

What if the solution looks unusual?

Do not inject it. Compare the leaflet and ask the dispensing pharmacy to assess the pen.

Summary

Saxenda 6mg/mL is a prescription liraglutide pen for defined weight-management use. Correct assessment, pack selection, training, storage and review matter. Use this page to identify the product, then follow the clinician and supplied leaflet.

Supporting safe follow-up

Keep a simple record of side effects, appetite changes, hydration and any problems operating the pen. Take this record and the current medicine list to reviews. It helps the prescriber decide whether the plan remains suitable and whether symptoms need investigation. Do not chase a numerical target by changing the pen setting yourself.

People with diabetes should follow the glucose-monitoring plan agreed with their care team. Reduced food intake can alter the effect of other treatments, so medication changes must be coordinated. Persistent vomiting, inability to drink or signs of dehydration deserve timely advice.

For travel, plan refrigeration, needles, sharps disposal and supporting documents in advance. Keep Saxenda in its original labelled packaging and avoid direct contact with ice. Airlines and destinations may have specific rules. If storage conditions cannot be maintained, ask a pharmacist what to do rather than using a pen of uncertain quality.